Publicacions en què col·labora amb Ricardo Blanco Alonso (90)

2023

  1. Corrigendum: The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases(Front. Immunol., (2023), 14, (1191782), 10.3389/fimmu.2023.1191782)

    Frontiers in Immunology

  2. Cranial and extracranial giant cell arteritis do not exhibit differences in the IL6 -174 G/C gene polymorphism

    Clinical and experimental rheumatology, Vol. 41, Núm. 4, pp. 910-915

  3. Cranial and extracranial large-vessel giant cell arteritis share a genetic pattern of interferon-gamma pathway

    Clinical and experimental rheumatology, Vol. 41, Núm. 4, pp. 864-869

  4. Ocular involvement in adult and paediatric patients with monogenic autoinflammatory diseases: a Spanish multicentre retrospective study

    Clinical and experimental rheumatology, Vol. 41, Núm. 10, pp. 2105-2114

  5. Optimisation of tocilizumab therapy in giant cell arteritis. A multicentre real-life study of 471 patients

    Clinical and experimental rheumatology, Vol. 41, Núm. 4, pp. 829-836

  6. The complex HLA-E-nonapeptide in Behçet disease

    Frontiers in Immunology, Vol. 14

  7. The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases

    Frontiers in Immunology, Vol. 14

2022

  1. Biologic therapy in refractory neurobehçet's disease: a multicentre study of 41 patients and literature review

    Rheumatology (Oxford, England), Vol. 61, Núm. 11, pp. 4427-4436

  2. IgA Vasculitis: Influence of CD40, BLK and BANK1 Gene Polymorphisms

    Journal of Clinical Medicine, Vol. 11, Núm. 19

  3. Intravenous methylprednisolone induces rapid improvement in non-infectious uveitis: a multicentre study of 112 patients

    Clinical and Experimental Rheumatology

  4. Tocilizumab in visual involvement of giant cell arteritis: a multicenter study of 471 patients

    Therapeutic Advances in Musculoskeletal Disease, Vol. 14

  5. Vascular endothelial growth factor haplotypes are associated with severe ischaemic complications in giant cell arteritis regardless of the disease phenotype

    Clinical and experimental rheumatology, Vol. 40, Núm. 4, pp. 727-733

2021

  1. Author Correction: BAFF, APRIL and BAFFR on the pathogenesis of Immunoglobulin-A vasculitis (Scientific Reports, (2021), 11, 1, (11510), 10.1038/s41598-021-91055-z)

    Scientific Reports

  2. BAFF, APRIL and BAFFR on the pathogenesis of Immunoglobulin-A vasculitis

    Scientific Reports, Vol. 11, Núm. 1

  3. Cranial and extracranial giant cell arteritis do not have different HLA-DRB1 and HLA-B association in Caucasian individuals

    Arthritis Research and Therapy

  4. Long-term Follow-up and optimization of infliximab in refractory uveitis due to Behçet Disease: National study of 103 white patients

    Journal of Rheumatology, Vol. 48, Núm. 5, pp. 741-750

  5. Role of the IL33 and IL1RL1 pathway in the pathogenesis of Immunoglobulin A vasculitis

    Scientific Reports, Vol. 11, Núm. 1

  6. Tocilizumab in refractory Caucasian Takayasu’s arteritis: a multicenter study of 54 patients and literature review

    Therapeutic Advances in Musculoskeletal Disease, Vol. 13

2020

  1. Biologic therapy in refractory non-multiple sclerosis optic neuritis isolated or associated to immune-mediated inflammatory diseases. A multicenter study

    Journal of Clinical Medicine, Vol. 9, Núm. 8, pp. 1-13

  2. Influence of IL17A gene on the pathogenesis of immunoglobulin-A vasculitis

    Clinical and experimental rheumatology, Vol. 38, Núm. 2, pp. 166-170